SCHEMBL4525481

SCHEMBL4525481

COc1cccc(Cl)c1CCl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.44
MAPT P10636 5/20 0.43
ALDH1A1 P00352 3/20 0.43
PLA2G1B P04054 1/20 0.43
POLB P06746 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
DPP4 P27487 1/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 2/20 0.40
HPGD P15428 3/20 0.40
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1291912 0.87 CA1 (0.50) L3MBTL1MAPTALDH1A1CA12CA1
SCHEMBL10987902 0.83 KDM4E (0.49) L3MBTL1MAPTALDH1A1PLA2G1BPOLB
SCHEMBL2446584 0.82 L3MBTL1 (0.43) L3MBTL1MAPTALDH1A1PLA2G1BPOLB
SCHEMBL2380131 0.82 DPP4 (0.62) L3MBTL1MAPTALDH1A1PLA2G1BPOLB
SCHEMBL695060 0.82 L3MBTL1 (0.43) L3MBTL1MAPTALDH1A1PLA2G1BPOLB
SCHEMBL695851 0.82 L3MBTL1 (0.43) L3MBTL1MAPTALDH1A1PLA2G1BPOLB
SCHEMBL27260267 0.82 L3MBTL1 (0.43) L3MBTL1MAPTALDH1A1PLA2G1BPOLB
Bromide SCHEMBL25371032 0.80 L3MBTL1 (0.42) L3MBTL1MAPTALDH1A1PLA2G1BPOLB
Hydrochloric Acid SCHEMBL2379527 0.80 DPP4 (0.61) L3MBTL1MAPTALDH1A1PLA2G1BPOLB
SCHEMBL687701 0.80 L3MBTL1 (0.50) L3MBTL1MAPTALDH1A1POLBDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103097364-B Spiro-piperidine derivatives as S1P modulators ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2015-11-25 CN disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 L3MBTL1 3517/4885MAPT 4692/4885ALDH1A1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.